140 related articles for article (PubMed ID: 29698618)
1. Response to 17-alpha hydroxyprogesterone caproate.
Frappaolo A; Vadnais M
Am J Obstet Gynecol; 2018 Aug; 219(2):217. PubMed ID: 29698618
[No Abstract] [Full Text] [Related]
2. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Owens L; Prager S
Obstet Gynecol; 2017 May; 129(5):945. PubMed ID: 28426603
[No Abstract] [Full Text] [Related]
3. The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth.
Nelson DB; Herrera CL; McIntire DD; Cunningham FG
Am J Obstet Gynecol; 2024 Jan; 230(1):1-9. PubMed ID: 37798189
[No Abstract] [Full Text] [Related]
4. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Berghella V; Owen J; Szychowski JM
Obstet Gynecol; 2017 Feb; 129(2):390-391. PubMed ID: 28121824
[No Abstract] [Full Text] [Related]
5. Regarding 'Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth'.
Deng Z; Lu D
Eur J Obstet Gynecol Reprod Biol; 2022 Mar; 270():246. PubMed ID: 35151530
[No Abstract] [Full Text] [Related]
6. Obstetric Indications for Progestin Therapy.
Boelig RC
Obstet Gynecol Clin North Am; 2023 Mar; 50(1):101-107. PubMed ID: 36822696
[TBL] [Abstract][Full Text] [Related]
7. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
Fried I; Beam AL; Kohane IS; Palmer NP
JAMA Intern Med; 2017 Nov; 177(11):1689-1690. PubMed ID: 28973537
[TBL] [Abstract][Full Text] [Related]
8. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
Romero R; Stanczyk FZ
Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669
[No Abstract] [Full Text] [Related]
9. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
10. Deus ex Makena?
Silver RM; Cunningham FG
Obstet Gynecol; 2011 Jun; 117(6):1263-1265. PubMed ID: 21471852
[No Abstract] [Full Text] [Related]
11. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
12. Progesterone for preterm birth prevention: the importance of informed consent.
Urato AC
Am J Obstet Gynecol; 2019 Mar; 220(3):290. PubMed ID: 30550768
[No Abstract] [Full Text] [Related]
13. Evaluation of 17-alpha hydroxyprogesterone caproate efficacy.
Hauspurg A; Caritis SN; Venkataraman R
Am J Obstet Gynecol; 2018 Feb; 218(2):261. PubMed ID: 28958584
[No Abstract] [Full Text] [Related]
14. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
15. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
[TBL] [Abstract][Full Text] [Related]
16. Immune effects of 17α-hydroxyprogesterone caproate.
Al-Lami RA
Am J Obstet Gynecol; 2022 Oct; 227(4):671-675. PubMed ID: 35779586
[No Abstract] [Full Text] [Related]
17. Some biological activities of certain progestogens. I. 17 alpha-Hydroxyprogesterone 17-n-caproate.
KESSLER WB; BORMAN A
Ann N Y Acad Sci; 1958 Jul; 71(5):486-93. PubMed ID: 13583805
[No Abstract] [Full Text] [Related]
18. Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
Caritis SN; Hauspurg A; Venkataramanan R; Lemon L
Am J Obstet Gynecol; 2018 Dec; 219(6):623-625. PubMed ID: 30171841
[No Abstract] [Full Text] [Related]
19. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population.
Hauth JC; Gilstrap LC; Brekken AL; Hauth JM
Am J Obstet Gynecol; 1983 May; 146(2):187-90. PubMed ID: 6682631
[TBL] [Abstract][Full Text] [Related]
20. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.
Attardi BJ; Zeleznik A; Simhan H; Chiao JP; Mattison DR; Caritis SN;
Am J Obstet Gynecol; 2007 Dec; 197(6):599.e1-7. PubMed ID: 18060946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
